Decreased Growth Inhibitory Responses of Squamous Carcinoma Cells to Interferon-γ Involve Failure to Recruit cki Proteins into cdk2 Complexes  by Harvat, Beth L. & Jetten, Anton M.
Decreased Growth Inhibitory Responses of Squamous
Carcinoma Cells to Interferon-g Involve Failure to Recruit cki
Proteins into cdk2 Complexes
Beth L. Harvat and Anton M. Jetten*
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina; *Laboratory of Pulmonary
Pathobiology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, U.S.A.
Interferon-g induces an irreversible growth arrest and
squamous differentiation in normal human epi-
dermal keratinocytes. We present for the ®rst time a
careful biochemical analysis of the cell-cycle-related
events that occur during interferon-g treatment of
normal human epidermal keratinocytes. The inter-
feron-g-induced irreversible growth arrest state is
characterized by inhibition of cyclin-dependent
kinases, prevention of Rb and p130 (Rb2) phos-
phorylation, and increases in p27Kip1, p16Ink4a, and
p130 proteins, together with a transient increase in
p21Waf1/Cip1. Cells derived from squamous cell carci-
nomas are less responsive to interferon-g and do not
terminally differentiate. We exploited these differ-
ences in response to interferon-g in order to identify
the particular molecular defects in cell cycle control
that promote carcinogenesis in squamous epithelia.
In several squamous cell carcinoma cell lines as well
as in interferon-g-insensitive HaCaT cells, interferon
g was unable to signi®cantly induce levels of p130
and/or p16 protein. In addition, p21 association with
cdk2 complexes was undetectable in either the
absence or the presence of interferon-g and, unlike
normal human epidermal keratinocytes, p27 associ-
ation with cdk2 did not increase with interferon-g
treatment. These multiple defects appear to be
intrinsic to the mechanisms of cell cycle regulation
rather than due to defects in the interferon-g signal-
ing pathway, as induction of several interferon-g-
responsive genes including Stat 1, IRF-1, and p21
itself was normal. Interestingly, exogenous expres-
sion of p21 protein in the squamous cell carcinoma
cell lines by adenovirus carrying wildtype p53 or p21
cDNA cooperated with interferon-g to produce a
greater inhibition of growth than either agent alone,
even though p21 protein could barely be detected in
cdk2 complexes. We conclude that squamous cell
carcinoma cells have intrinsic defects in their ability
to regulate cdk±cki complexes in response to differ-
entiation signals. Key words: keratinocyte/p27Kip1/
p21WAF1/Cip1/p130. J Invest Dermatol 117:1274±1281,
2001
S
quamous differentiation is a multistep process common to
epithelia from many tissues, including epidermis, esopha-
gus, cervix, and vagina. Keratinocytes stimulated to
differentiate undergo irreversible withdrawal from the
cell cycle and a sequential expression of squamous-speci®c
genes. The squamous differentiation program can be triggered by
growth of keratinocytes to con¯uency, culture in suspension, or
treatment with phorbol ester (Hawley-Nelson et al, 1982; Adams
and Watt, 1989). We reported that interferon-g (IFN-g) can induce
growth arrest and expression of squamous differentiation-speci®c
genes in a time- and dose-dependent manner in normal human
epidermal keratinocytes (NHEK) (Saunders and Jetten, 1994) and
in normal mammary epithelial cells (Harvat and Jetten, 1996). IFN-
g can also inhibit growth of human papillomavirus-transformed
cervical keratinocytes (Delvenne et al, 1995).
The IFN-g signal transduction pathway involves receptor
aggregation by IFN-g and subsequent activation of Jak 1 kinase,
which then phosphorylates the transcription factor Stat 1 and causes
its translocation to the nucleus (reviewed in Darnell et al, 1994).
The connection between this IFN-g-mediated signaling pathway
and the induction of growth arrest is not well understood. Both Stat
1 and IRF-1, a target gene for Stat 1 transactivation, have been
implicated in growth control in keratinocytes (Arany et al, 1996;
Hecker et al, 1996; Flodstrom and Eizirik, 1997; Fujimura et al,
1997; Nakanishi et al, 1997; Jackson et al, 1999).
Regulation of cell cycle progression in mammalian cells by
external factors is controlled primarily by the cyclin-dependent
kinases (cdk). The activity of these kinases is regulated at a number
of levels, including phosphorylation and association with cyclins or
cdk inhibitor (cki) proteins (Morgan, 1995). Details of how the
IFN-g signaling pathway affects cell cycle regulation are only
beginning to be understood. In particular, expression of
p21WAF1/Cip1 has been shown to be directly regulated by Stat 1
via a GAS response element in the p21 promoter (Chin et al, 1996).
We have previously reported that, during squamous differentiation
induced by suspension culture, cdk activity is inhibited and levels of
two cki proteins, p27Kip1 and p16Ink4a, are increased, whereas
p21Cip1/WAF1 is transiently increased and then downregulated
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(Harvat et al, 1998). Levels of the Rb family member p130 also
increase during differentiation. These events in concert require a
speci®c activation of the differentiation program and do not occur
when growth arrest is induced by overexpressing one of the cki
proteins.
We previously reported that squamous cell carcinoma (SCC) cell
lines have greatly decreased sensitivity to the growth inhibitory
effects of IFN-g (Saunders et al, 1994). As IFN-g most probably
serves as an in vivo regulator of keratinocyte proliferation (Saunders
et al, 1996; Jackson et al, 1999), the ability of cells to escape this
regulation could contribute signi®cantly to carcinogenesis. To
determine the defects in cell cycle control that render SCC cells less
sensitive to IFN-g, we have examined the effects of IFN-g on
normal growth regulatory processes in NHEK and compared the
results to those observed in several carcinoma cell lines and the
spontaneously immortalized epithelial cell line HaCaT. For further
comparison, we have also used a clone of primary human
keratinocytes that has been given an extended life span following
stable transfection with a plasmid carrying the cancer-associated
virus HPV-18 but retains the ability to differentiate (HPVK). Our
studies reveal that IFN-g induces multiple changes in cki and Rb
family members in their levels, phosphorylation, or association with
cdk. In SCC cells, however, these changes are severely comprom-
ised due to what appears to be intrinsic defects in the mechanisms
of cell cycle control and not defects in IFN-g signaling pathways.
MATERIALS AND METHODS
Cell lines and culture NHEK cells (neonatal) were obtained from
Cascade Biologics (Portland, OR) and grown in KGM-2 complete
medium (Clonetics, LaJolla, CA). SCC13, SQCCY1 (SCCY1) cells, and
HaCaT cells, as previously described (Saunders and Jetten, 1994), were
grown in Medium 154 supplemented with human keratinocyte growth
supplement (HKGS) (Cascade Biologics). HPVK (clone 18-1) was
derived by stable integration of the plasmid pHPV-18 containing the
HPV type 18 genome in pBR322 (a gift from Dr. deVilliers, German
Cancer Center, Heidelberg, Germany). NHEK cells were cotransfected
with pSV2-Neo and pHPV-18 using lipofectin, then grown for 2 d, and
selected in G418, and individual clones were isolated. All cell lines have
tested negative for mycoplasma contamination. Cells used in
synchronized studies were washed twice with KGM-2 medium lacking
epidermal growth factor (EGF) and bovine pituitary extract and placed in
the same medium containing 0.5 mg per ml EGF-receptor blocking
antibody (Upstate Biotechnology, Lake Placid, NY). After 24 h, the
medium was removed, and the cells were washed twice and then refed
in prewarmed complete KGM-2.
Proliferation assays and cell cycle analysis, [3H]-thymidine
incorporation, BrdU incorporation, and analysis by ¯ow
cytometry These have been previously described (Harvat and Jetten,
1996).
Immunoblot and coimmunoprecipitation/Western studies
These studies have been previously described (Harvat and Jetten, 1996).
Purchased antibodies include cdk2, cyclin D1, and cyclin E rabbit
polyclonal antibodies from UBI; p53 mouse monoclonal and IRF-1 E-
cadherin (1:500) and I-CAM (1:500), Rb, p130, and cdk6 rabbit
polyclonal antibodies from Santa Cruz Biotechnology (Santa Cruz, CA);
Stat 1 and p27Kip1 mouse monoclonal antibodies from Transduction
Laboratories (Lexington, KY); and p21/Waf-1 mouse monoclonal
antibody from Oncogene Science (Cambridge, MA). Cdk4 rabbit
polyclonal antibody came from Yue Xiong (University of North
Carolina, Chapel Hill, NC), p16/15 (JC6) mouse monoclonal from Jim
Koh (Massachusetts General Hospital, Boston, MA), and cyclin A rabbit
polyclonal from Michele Pagano (New York University). Secondary
antibodies used were peroxidase-conjugated mouse or rabbit anti-IgG
(Fab fragment or species absorbed) from Chemicon (Temecula, CA).
Northern analysis The northern analysis has been previously
described (Harvat and Jetten, 1996). cDNAs used for probes were kindly
provided as follows: Stat 1 by Dr. J.E. Darnell, Jr. (Rockefeller
University, New York, NY), guanylate binding protein by Dr. B. Rubin
(Fordham University, New York, NY), p16Ink4a by Dr. D. Beach (Cold
Spring Harbor, NY), p21Waf1/Cip1 by Dr. J. Fontana (University of
Maryland, Baltimore), and p27Kip1 by Dr. J. Massague (Memorial Sloan
Kettering Cancer Center, NY).
Kinase assays The kinase assays were done as previously described
using either a GST-C-terminal Rb fusion protein or histone H1 as
substrate (Harvat et al, 1998).
Adenovirus infection Cells were plated at least 2 d prior to
infection. Cells counts were obtained by trypsinizing a sample dish at the
time of infection. For infection, the medium was replaced with 0.5 ml
(six-well plates) or 1.0 ml (60 mm dishes) medium lacking bovine
pituitary extract and containing adenovirus at the desired m.o.i. Plates
were incubated with occasional rocking for 90 min in a 37°C, 5% CO2
incubator, and then an additional 1.5 or 4.0 ml of complete medium was
added and the plates were incubated for 24 h prior to treatment or
harvest. Recombinant viruses Adnull, Adp21, and Adp53 were a kind
gift from Prem Seth (Katayose et al, 1995).
RESULTS
IFN-g inhibits proliferation of NHEK within 24 h, but only
partially retards growth in SCC cells after 48 h The effect
of IFN-g on proliferation in NHEK and various immortal cell lines
is demonstrated in Fig 1. IFN-g treatment for 24 h dramatically
reduced the extent of 3[H]-thymidine incorporation in NHEK
(85% of control) and HPVK (70%), but had no effect on the SCC
cell lines SCC13 and SQCC/Y1 (SCCY1) or on the spontaneously
immortalized epithelial cell line HaCaT (Fig 1A). 3[H]-thymidine
incorporation in these cell lines was reduced after 48 h or more of
treatment with IFN-g, however, although never reaching the
degree of inhibition seen in NHEK cells. Flow cytometric analysis
of NHEK treated over a period of 48 h with IFN-g revealed that
cells accumulated in G1 with a concomitant loss of cells in S phase
(Fig 1B), whereas the percentage of cells in G2/M remained
constant. Inhibition of S phase entry was supported by studies
indicating that the percentage of cells that incorporated BrdU after
a 30 min pulse dropped from 12% to 2% during this time period
(data not shown). NHEK cells can be synchronized in G0 by
withdrawal of EGF from the medium for 24 h, and when
restimulated by addition of EGF to the medium, a wave of 40%±
60% of the cells will reenter the cell cycle initiating S phase 12±
14 h later (data not shown). When IFN-g is added to the
synchronized culture within the ®rst 6±8 h of release by EGF,
the progression through G1 into S phase, measured as
incorporation of 3H-thymidine 14 h after EGF addition, is
blocked. Addition of IFN-g later than 8 h after EGF addition has
no effect on progression into S phase (Fig 1C), indicating that the
cells have become refractory to IFN-g growth inhibition. These
studies indicated that IFN-g induces a mid-G1 arrest in
keratinocytes.
Consistent with these ®ndings, we found that treatment of
NHEK with IFN-g resulted in loss of the hyperphosphorylated
forms of Rb and p130 within 24 h (Fig 1D). The level of Rb
protein, which is regulated in part by autorepression of the Rb
promoter (Shan et al, 1994), decreased rapidly with the appearance
of hypophosphorylated Rb whereas, interestingly, the level of total
p130 consistently increased 2±3-fold in several independent
experiments. Loss of cyclin A protein, a prototype of the E2F/
Rb-regulated genes, followed a similar time course as the loss of
phosphorylated Rb. As we have reported for other inducers of
squamous differentiation (Harvat et al, 1998), IFN-g treatment
increased levels of three cki in NHEK, p16, p21, and p27. p16Ink4a
and p21Waf1/Cip1 expression were upregulated at both the mRNA
and protein level (Fig 1D, data not shown), whereas only the
protein levels of p27Kip1 were induced. The induced levels of p21
were not sustained, returning to baseline levels by 48 h after
treatment.
The IFN-g signaling pathway is intact in all cell lines
tested The inability of IFN-g to inhibit proliferation in a timely
fashion in SCC cell lines could be due to defects in the IFN-g
signaling pathway or intrinsic defects in cell cycle regulation. IFN-g
activates expression of several genes, including two IFN-g-
responsive transcription factors, Stat 1 and IRF-1, and a third
gene, guanylate binding protein, all of which have been implicated
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in cell cycle control (Kirchoff et al, 1993; Pine et al, 1994; Sun et al,
1999). IFN-g was able to induce the expression of these three genes
in all of the cell lines at the protein level (Fig 2A; Saunders et al,
1999) and mRNA level (Fig 2B). As expression of these genes
involves IFN-g stimulation through its receptor of a tyrosine kinase
cascade that targets the transcription factor Stat 1 for activation and
nuclear translocation (Darnell et al, 1994), these data indicate that
the upstream IFN-g signaling pathway is intact. Therefore, we
turned our attention to analyzing differences in cell cycle
regulation.
Activation of Rb family members and inhibition of cdk
activity is delayed in SCC cell lines In contrast to the
observations in NHEK, changes in cell cycle regulatory proteins in
the less sensitive cells were minimal in response to IFN-g. Rb
phosphorylation and expression was only partially downregulated
in the cell lines that were less sensitive to IFN-g-induced growth
arrest, and Rb-regulated cyclin A synthesis was not repressed even
after 36 h of IFN-g treatment (Fig 3). There was also little
induction in p130 protein levels, although the protein appeared to
become less phosphorylated. In contrast, IFN-g-sensitive HPVK
did not express detectable levels of Rb and p130 proteins,
consistent with the ability of the E7 protein of HPV type 18 to
inactivate these proteins (Berezutskaya et al, 1997). Following IFN-
g treatment, however, small amounts of hypophosphorylated Rb
and p130 could be detected and cyclin A expression was inhibited
in HPVK. These results, together with the data in Fig 1, suggest
that Rb and p130 are converted to active forms within 24 h of
IFN-g treatment in IFN-g-sensitive cells, thus blocking progression
into S phase, but are converted more slowly in cells less sensitive to
IFN-g.
This ®nding led us to the question of whether the effect of IFN-g
on cdk activity, which is responsible for phosphorylating Rb and
p130 in NHEK, differs in SCC cells. In normal keratinocytes, the
activities of cdk2, cdk4, and cdk6 were inhibited by 36 h of IFN-g
treatment, as demonstrated by immunoprecipitation of cdk com-
plexes by either their cognate cdk antibody or an antibody directed
against cyclin E (Fig 4A, data not shown). We focused on cdk2
activity because we have previously reported that cdk2 inhibition
correlates most closely with irreversible withdrawal from the cell
cycle in differentiating keratinocytes (Harvat et al, 1998), an event
that occurs within 4±8 h of cells receiving a differentiation signal.
Cdk2 activity, measured by phosphorylation of histone H1, was
likewise inhibited in sensitive HPVK by 36 h of IFN-g treatment.
At 36 h of treatment, however, cdk2 activity was only partially
inhibited in the HaCaT and SCC cell lines (Fig 4B). Longer
incubation with IFN-g continued to gradually decrease cdk2
activity in these cells (data not shown), suggesting that the kinetics
of cdk inhibition were markedly slower in IFN-g-resistant cells
than in sensitive cells.
We have previously reported that resistance to IFN-g in
mammary carcinoma cell lines could be attributed in part to
overexpression of cyclin E and cdk2 (Harvat et al, 1997). Cdk and
Figure 1. IFN-g-induced growth arrest. (A) Asynchronous cultures
of each cell type were treated with 200 U per ml IFN-g for the times
indicated, then pulsed with 1 mCi per ml 3H-methyl-thymidine for
60 min, and harvested. The incorporated counts were measured in a
scintillation counter. Comparable results were obtained in two
independent experiments. (B) Asynchronous NHEK treated with 200 U
per ml IFN-g for the times indicated were pulsed with 10 mM BrdU for
30 min prior to harvest. Cells were then trypsinized and stained with
¯uorescein isothiocyanate labeled anti-BrdU and propidium iodide.
DNA content was analyzed by ¯ow cytometry and ImageQuant
software. The graph represents the analysis of the propidium iodide
histogram. BrdU results are discussed in Results. (C) NHEK were
synchronized by EGF starvation as described in Materials and Methods and
IFN-g was added to the medium at various times following restimulation
with EGF. Cells were harvested at 14 h following addition of EGF and
analyzed for the amount of incorporated 3H-thymidine. Results are
plotted with respect to the 3H-thymidine incorporation in control cells
receiving only EGF, which was arbitrarily set at 100%. (D) Immunoblot
analysis of the effects of IFN-g on cell cycle regulatory proteins in a time
course following addition of 200 IU IFN-g to asynchronous,
proliferating NHEK. Arrows indicate hyperphosphorylated bands. Equal
amounts of protein were loaded in each lane per blot, except for the
extra ®rst lane in the p130 blot, which has three times more protein than
the rest of the lanes. The extra overloaded lane was included because the
most hyperphosphorylated form of p130 is dif®cult to see due to the low
level of p130 protein in untreated cells.
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cyclin protein levels in the HaCaT and SCC cell lines tested,
however, were remarkably similar to those in NHEK (Fig 5A),
although elevated levels of cdk4 and cdk6 have been reported in
some SCC lines (Patel et al, 1997). These data indicate that changes
in the levels of cdk and G1 cyclins are not responsible for the
reduced inhibition of Rb phosphorylation.
The effects of IFN-g on the cki in the insensitive cell lines,
however, were strikingly different from NHEK. Both p16Ink4a
mRNA and protein are absent in SCC13 as reported by others
(Loughran et al, 1996); mRNA and protein were likewise
undetectable in our hands in SCCY1 cells, whereas low levels of
p16 mRNA were present in HaCaT cells but p16 protein was not
detected (Fig 5B, C). Thus, the absence of p16 could contribute to
unresponsiveness to IFN-g. Consistent with the reported repression
of p16 expression by Rb (Li et al, 1994; Hara et al, 1996), HPVK
cells have very high amounts of p16 protein and mRNA that are
moderately decreased with IFN-g treatment in conjunction with
the appearance of hypophosphorylated Rb.
Both the basal and IFN-g-induced levels of p21 protein and
mRNA were markedly lower in SCC cells than those in NHEK or
HPVK. The ratio of cki proteins to cdk is critical in regulating
kinase activity, as the level of cki must reach a threshold to be
effective (Sherr and Roberts, 1995). Densitometric analysis of the
results in Fig 5 indicated that the fold induction of p21 protein and
mRNA in the carcinoma cells was equivalent to or greater than that
in NHEK (Fig 5D, data not shown). The ratio of p21 to cdk2
levels, however, was 37±500 times lower in untreated carcinoma
Figure 2. IFN-g induces expression of genes in the IFN-g
signaling pathway in all the cell lines tested. (A) Immunoblot for
protein levels of the IFN-g-inducible genes, Stat 1 and IRF-1, in
untreated cells or cells treated for 24 h with IFN-g. Longer exposures of
the protein blots revealed expression of Stat 1 and IRF-1 in untreated
cells at low levels in all cell types. (B) mRNA levels of Stat 1, IRF-1,
and guanylate binding protein analyzed by successive hybridization with
each probe on the same blot. Thirty micrograms of total RNA were
loaded in each lane and glyceraldehyde dehydrogenase serves as a loading
control.
Figure 3. Comparison of effects of IFN-g on Rb phosphorylation,
p130, and cyclin A in SCC cell lines. Cells were treated with 200 IU
IFN-g for 36 h where indicated and lysates were analyzed by
immunblot.
Figure 4. IFN-g inhibits G1 cdk activity more effectively in
sensitive cells. (A) Kinase activity using puri®ed GST-Rb C-terminal
fusion protein (Guan et al, 1994) as substrate. The antibody used to
immunoprecipitate the kinase complex is indicated on the right; p
denotes that the immunoprecipitating antibody was ®rst neutralized by
its cognate peptide before being added to untreated lysate; the numbers
represent hours after IFN-g addition. (B) Immunoprecipitated cdk2
activity towards histone H1 from untreated cells and cells treated with
IFN-g for 36 h.
Figure 5. IFN-g treatment has no effect on levels of cdk and
cyclins, but induces increases in speci®c cki proteins. (A), (B)
Western blots were performed on extracts of untreated cells or cells
treated with IFN-g for 24 h or 36 h. Twenty micrograms of total
protein was loaded in each lane except for the p16 blot, for which
100 mg of protein was used. (C) The same RNA blot used in Fig 3 was
reprobed for p21, p16, and p27 expression. The p16 results are over
exposed to clearly demonstrate lack of detectable mRNA in SCC13 and
SCCY1 cells. (D) Densitometry analysis of the relationship of expression
levels of p27 and p21 in treated and untreated cells in (B) and in
reference to cdk2 levels shown in (A).
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cells and 12±42 times lower in treated SCC cells than in NHEK,
suggesting another intrinsic regulatory defect that could contribute
to unresponsiveness to IFN-g. The induction of p21 by IFN-g
appeared to be unrelated to p53 expression, which was down-
regulated in NHEK with IFN-g treatment (Fig 5B). In addition,
p53 is undetectable in HPVK and mutated in the SCC and HaCaT
cell lines.
In contrast, basal levels of p27 protein in the immortal cell lines
were equivalent to or greater than that found in NHEK, but barely
detectable in untreated HPVK (Fig 5B). The fold induction of p27
in HPVK by IFN-g was more dramatic than that in the normal
cells, re¯ecting the lower basal levels. Both carcinoma cell lines
appeared to be able to minimally induce p27 levels in response to
IFN-g, whereas p27 levels in HaCaT cells showed no response. As
has been reported by others (Sherr and Roberts, 1995), the
regulation of p27 levels appears to occur at the post-transcriptional
level, as no signi®cant changes were seen in the levels of p27
mRNA for any of the cell types after treatment with IFN-g
(Fig 5C).
P27 and p21 increase in cdk complexes within 36 h in IFN-g-
responsive cells, but not in less sensitive cell lines We next
analyzed the association of p27 and p21 with cdk2 by
immunoprecipitating cdk2 complexes under nondenaturing
conditions. As seen in Fig 6, p27 and p21 protein was associated
with cdk2 both in proliferating NHEK and in cells treated with
IFN-g. Importantly, the IFN-g-induced levels of p21 and p27 were
re¯ected as an increased association with cdk2, suggesting the
increases are at least partially the mechanism by which IFN-g
inhibits cdk activity. Despite being modestly induced in the
carcinoma cells, the amount of p27 protein in cdk2 complexes did
not increase with IFN-g treatment in any of the resistant cell types.
Even more dramatically, complexes of p21 and cdk2 were
undetectable in the resistant cell types, even though IFN-g
treatment caused induction of p21 protein levels. This cannot be
attributed to technical problems of detection of the lower levels of
p21 protein in complexes, because an equally low level of p21 in
untreated HPVK was detectable in complexes with cdk2 (compare
lanes 8 and 9 in Figs 5B, 6).
Adenoviral-mediated expression of p53 in SCC cells raises
basal levels of p21 and cooperates with IFN-g in inhibiting
growth Keratinocytes from p53 null mice have lower basal
levels of p21 protein, indicating an essential role for p53 in
regulating p21 expression in keratinocytes (Weinberg et al, 1997).
As all of the resistant cell lines that were used in this study are either
null or mutant for p53, we examined whether the low basal levels
of p21 could be related to this phenomenon. Introduction of
wildtype p53 by infection with an adenovirus construct carrying
p53 cDNA (Katayose et al, 1995) was able to induce the basal level
of p21 in each of the SCC cell lines in a dose-dependent manner
within 24 h (Fig 7A), indicating that the ability of p53 to activate
expression from the p21 promoter was intact in these cells.
We next determined whether the presence of p53 or the
resulting increase in p21 was suf®cient to increase the sensitivity of
the cells to IFN-g. Using an m.o.i. that gave approximately the
same levels of expression of p53 and p21 in the two cell lines, we
demonstrated that expression of p53 alone decreased the amount of
3H-thymidine incorporation in SCC13 cells in the absence of IFN-
g (Fig 7B). Treatment with IFN-g had an additional negative effect
on growth, however, causing 75% inhibition of 3H-thymidine
incorporation in 48 h compared with 36% inhibition in the parent
cell line (Fig 1 compared with Fig 7B). This inhibition in growth
was paralleled by a decrease in cdk2 activity, even though p21 still
could not be detected in cdk2 immunoprecipitated complexes
(Fig 7C, data not shown). In the case of SCCY1 cells that contain
no detectable endogenous protein, p53 expression had no effect by
itself, but clearly sensitized cells to growth inhibition by IFN-g,
increasing inhibition from 45% in the parent cells after 48 h of
treatment to 86% in the p53-expressing cells. The differences in
response between the two SCC cell lines emphasize that a variety
of genetic defects can occur in SCC, leading to different
phenotypes. One potential cause for the difference between the
two cell lines tested here could be their p53 statusÐone
overexpressing a mutant form and the other having virtually no
expression.
Interestingly, p53-induced expression of p21 did not change the
kinetics of the response to IFN-g. SCC cells expressing wildtype
Figure 6. IFN-g effects on association of p21 and p27 with cdk2.
Cdk2 complexes were immunoprecipitated from extracts of untreated
cells or cells treated for 36 h with 200 U per ml IFN-g. A single
Western blot was probed successively for levels of p27, p21, and cdk2
found in the complex.
Figure 7. Expression of p53 in SCC cell lines causes an increase
in p21 expression and reduces 3H-thymidine incorporation. (A)
Immunoblots detecting the levels of p53 and p21 expression after
infection by various amounts of an empty adenovirus, Adnull, or an
adenovirus carrying p53 cDNA, Adp53. Cell extracts were harvested
24 h after infection. (B) Measurement of 3[H]-thymidine incorporation
after the indicated times following adenovirus infection and treatment
with 200 U IFN-g or vehicle. SCC13 cells were infected at an m.o.i. of
5 and SCCY1 cells at an m.o.i. of 50 based on the levels of p53 and p21
expression detected in (A) and treated the following day with IFN-g.
Error bars represent standard deviation. (C) Lysate from cells infected
and treated as in (B) for 48 h were analyzed for expression levels of p27
and p21 by immunoblot. Cdk2 complexes were immunoprecipitated
from 100 mg protein of the same lysate. The immunoprecipitate was
analyzed for kinase activity towards a histone H1 substrate and for the
presence of p27 and p21 in the complex by immunoblot.
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p53 and treated for only 24 h with IFN-g still demonstrated little
response, implying that the increased expression of p21 was
insuf®cient to expedite the effects of IFN-g signaling as it relates to
inhibition of cdk activity.
As p53 expression could have effects at multiple levels, we tested
whether the additional response to IFN-g was directly due to the
increased expression of p21 by infecting cells with an adenovirus
carrying the cDNA for p21Cip1. As predicted, exogenous expres-
sion of p21 inhibited growth of the SCC cell lines in a dose-
dependent fashion (Fig 8A). At levels of infection by Adp21 that
had little (SCC13, 10 m.o.i.) or modest (SCCY1, 50 m.o.i.)
inhibition of 3[H]-thymidine incorporation, the effect of IFN-g on
growth inhibition was additive with that induced by the expression
of p21 (Fig 8B for expression levels of p21 and p27). In this case,
we could detect some p21 protein in cdk2 complexes, although it
was less than detected in complexes from proliferating HPVK
(Fig 8C). Nevertheless, cdk2 activity was signi®cantly decreased by
expression of p21 (Fig 8C). Taken with the data in Fig 7, we
conclude that SCC cells are responsive to wildtype p53 and p21 in
a normal manner.
IFN-g treatment of the p21-expressing cells did not have any
additional effect on cdk2 activity, however, or the amount of p21
and p27 associated with cdk2 (these appear to even be slightly
reduced in response to IFN-g), even though the amount of 3[H]-
thymidine incorporation was further reduced. These ®ndings
suggest that there may be additional IFN-g-sensitive targets that
participate in growth arrest of SCC cells, but also con®rm the
inability of IFN-g to promote cdk2±cki complex formation in these
SCC cells despite large amounts of p21 protein being present.
Interestingly, whereas the decrease in cdk2 activity due to p21
overexpression correlated with the appearance of hypophosphory-
lated forms of p130 in SCC13, p130 remained hyperphosphory-
lated in p21-expressing SCCY1 cells (Fig 8B). In addition, p21
expression had very little, if any, effect on the inability of IFN-g
treatment to induce increases in p130 protein levels in either cell
line.
DISCUSSION
We demonstrate here that the irreversible growth arrest induced
during IFN-g-mediated terminal differentiation of keratinocytes
involves accumulation of cells with both a 2N and 4N DNA
content, but a reduction of cells in S phase. Despite the presence of
nearly 30% of cells in G2 when cdk2 is normally active and Rb
proteins are hyperphosphorylated, IFN-g-treated cultures show
inhibition of G1 cdk and complete prevention of Rb and p130
hyperphosphorylation within 24 h. These events are associated
with an upregulation of p16, p21, and p27 cki as well as an
upregulation of the level of p130 protein. Similar events occur
during terminal differentiation of NHEK induced by suspension
culture and we have demonstrated that these events are the result of
a speci®c differentiation signal and not growth arrest per se (Harvat
et al, 1998). In those studies, growth arrest induced by over-
expression of any of the cki was not suf®cient to induce
differentiation or promote the upregulation of the cki proteins or
p130. The question of whether their upregulation was required for
this differentiation program was not addressed. The fact that IFN-g
triggers the same events, however, suggests that upregulation of the
cki and p130 are integral parts of squamous differentiation and lends
credence to the hypothesis that they are required, if not to establish
commitment to differentiation, then at least to maintain the
differentiated state. This hypothesis is further supported by several
other reports: p130 and p21 are restricted in the epidermis to cells
already committed to differentiation in the suprabasal compart-
ments (Matsuta et al, 1997; Paramio et al, 1998); second, if the
balance of signals promoting proliferation and differentiation is
altered in suprabasal layers, suprabasal keratinocytes will reenter the
cell cycle (Pelengaris et al, 1999).
The correlation of reduced response to IFN-g for growth
inhibition and its inability to induce cki association with cdk2
suggests that regulation of cdk2 activity may be required for
terminal differentiation. The growth inhibitory role of Rb,
however, appears not to be essential for differentiation-associated
growth arrest, as HPVK that do not express Rb respond to IFN-g
and growth arrest in nearly the same temporal pattern as NHEK.
These data are consistent with the ®nding that cyclin D1, a
regulator of Rb, has no role in squamous differentiation (Robles
et al, 1996). Cki inhibition of cdk2 activity towards other targets
that are essential for S phase entry or progression such as
centrosome duplication (Nakayama et al, 2000) may be suf®cient
to mediate IFN-g effects. Alternatively, cki proteins may have
additional roles in IFN-g-induced differentiation and growth arrest.
In this regard, upregulation of p27 levels has been shown to be
necessary for activation of Stat 3, an event that is associated with
keratinocyte differentiation (Hauser et al, 1998). Distinguishing
Figure 8. Expression of p21 in SCC cell lines will inhibit 3H-
thymidine incorporation and cdk2 activity, but IFN-g treatment
has no effect or even reduces the amount of p21 and p27 in cdk2
complexes. (A) Measurement of 3[H]-thymidine incorporation
following adenovirus infection at various m.o.i. and treatment for 48 h
with 200 U IFN-g or vehicle. (B) SCC13 cells were infected at an
m.o.i. of 10 and SCCY1 cells at an m.o.i. of 50 based on results in (A)
and treated the following day with IFN-g. Lysates were made after 48 h
of treatment and total levels of p27 and p21 were measured by
immunoblot. The same amount of protein from lysates of uninfected
cells was loaded in lanes 1 and 6 for comparison. An immunoblot for
p130 was done on the same lysates. (C) Cdk2 complexes were
immunoprecipitated from 100 mg of total lysate protein. The
immunoprecipitate was analyzed for kinase activity towards a histone H1
substrate and for the presence of p27, p21, and cdk2 in the complex by
immunoblot. Cdk2 complexes were also immunoprecipitated from
100 mg protein of a lysate from untreated HPVK cells to use as a positive
control for the coimmunoprecipitation of p21 and p27 protein.
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between these two potential roles for the cki proteins in epidermal
terminal differentiation will have an impact on the design of new
drugs for topical application in the treatment of nonmelanoma skin
tumors, particularly if the objective of the treatment is to induce
terminal differentiation that will lead to the maturation and
shedding of tumor cells.
Cancer is caused by multiple genetic alterations that deregulate
growth control mechanisms and frequently promote dedifferentia-
tion or block terminal differentiation. In order to understand the
critical genetic defects that promote carcinogenesis in squamous
epithelium and keratinocytes in particular, we have analyzed several
cell lines that are resistant to IFN-g-induced terminal differentiation
and growth arrest. We show that resistance to IFN-g is accom-
panied by greatly delayed kinetics in cdk inhibition. Several
apparent defects were identi®ed in the regulation of cki that could
be part of the mechanism by which these cells are less responsive to
IFN-g-mediated growth inhibitory signals.
Two of these defects, lack of p16 expression and low p21 levels,
have been described in primary tumors and the genetic basis for the
defect is known. p16 protein and mRNA expression in the SCC
lines were below detectable limits, consistent with a number of
reports that document deletion or silencing by methylation of the
p16Ink4 gene in head, neck, and esophageal squamous carcinomas
(Yeudall et al, 1994; Zhou et al, 1994; El Naggar et al, 1997;
Tanaka et al, 1997; Timmerman et al, 1997) and non-small-cell
lung carcinomas (up to 50% of which are classi®ed as squamous
carcinomas; Kratzke et al, 1996). We speculate that p16 may be
essential to maintain cdk4/6 inhibition and the hypophosphory-
lated state of the elevated levels of p130, as cdk4, cdk6, and cyclin
D1 expression persists in differentiated cells. The role of p130, in
turn, may be important for maintaining the cell in the differentiated
and quiescent state.
The basal expression of p21WAF1/Cip1 was much lower in the
resistant cells than in sensitive NHEK or HPVK. These data are
consistent with the known occurrence of p53 mutations in SCC
(Leffell, 2000) and decreased p21 levels seen in keratinocytes from
p53 null mice (Weinberg et al, 1997). The p21 promoter contains a
Stat 1 response element (Chin et al, 1996). The induction of p21 by
IFN-g, as well as the normal response of other target genes in the
IFN-g signaling pathway including IRF-1 and Stat 1, is evidence
that the IFN-g/Stat 1 signaling pathway regulating gene expression
is intact in the SCC lines tested. Due to the low basal levels of p21,
however, the absolute level of p21 after IFN-g treatment remained
signi®cantly lower than that in sensitive cells. Lower p21 levels
could increase the ability of cells to progress through G1 into S
phase and, in fact, have been reported to aid in the assembly of cdk
complexes and actually enhance cdk activity (LaBaer et al, 1997).
At higher levels of adenovirus infection, p21 overexpression was
suf®cient to inhibit growth by itself. Overexpression of p21 inhibits
cell growth in HaCaT cells as well (Kallassy et al, 1998). We have
also seen that recombinant p27 protein can effectively inhibit cdk2
activity in complexes immunoprecipitated from SCC13 cells
(unpublished data), suggesting that the cdk2 complexes in IFN-g
insensitive cells are not inherently resistant to inhibition by cki
proteins. That increased expression of p21, driven either directly by
exogenous p21 cDNA or indirectly by exogenous p53 cDNA,
cooperates with IFN-g to produce a higher degree of cell cycle
arrest suggests that the threshold effect of p21 levels may have a role
in IFN-g-mediated inhibition of growth.
The third defect we identi®ed, failure of IFN-g treatment to
recruit p27 and p21 to cdk complexes despite an increase in protein
levels, has not been previously described and suggests there may be
an additional genetic lesion affecting the regulation of complex
assembly or stability. In fact, we were unable to detect p21 in
complexes with cdk2, whereas such complexes were readily
detected in sensitive cells and increased with IFN-g treatment for
24 h. The increased level of p21 achieved by exogenous p53
expression did not overcome this defect, although it sensitized
SCCY1 cells to IFN-g and had an additive growth inhibitory effect
with IFN-g in SCC13 cells. If p21 does not associate with cdk2 in
Adp53-infected SCC cells, how does it accomplish the cooperative
action? One possible explanation is that, given the role of low levels
of p21 in promoting cdk and cyclin association and thus progression
through G1, it is possible that the exogenous overexpression of p21
drives the cells to a certain cell cycle state where differentiation
signals are more effective. Alternatively, inhibition of proliferating
cell nuclear antigen or another cdk target for p21 may be critical for
irreversible growth arrest. A truncated form of p21 that was
mislocalized to the cytoplasm has been detected in a variety of
transformed cell lines (Poon and Hunter, 1998), suggesting that p21
expression may be processed differently in tumor cells.
Exogenously expressed protein may interfere with this process.
Phosphorylation of p21 could also potentially be different in tumor
cells. These questions must be further explored to better understand
the role of p21 in squamous differentiation and tumorigenesis.
We found that inhibition of cdk2 activity in HPVK was
comparable to that in NHEK, in contrast to the report of Jones et al
(1997) that HPV-16 E7 protein abrogates p21-mediated inhibition
of cdk2. This apparent discrepancy may be related to the fact that
the HPVK clone we used expresses HPV-18 viral proteins instead
of HPV-16 or more likely is due to the unique ability of this clone
both to have a greatly extended life span and to respond to
differentiation signals. This difference between results lends support
to the hypothesis that the function of the Cip family of cki proteins
is critically linked to the ability to differentiate.
In addition to failure to recruit p21 to cdk complexes, p27 levels
were upregulated to a lesser degree in SCC cell lines than in NHEK
or HPVK and the amount of protein recruited into cdk2 complexes
was unchanged by IFN-g, suggesting a failure to reach the critical
threshold necessary for kinase inhibition. Several lines of evidence
suggest that targeting of p27 by differentiating agents such as IFN-g
could be critical to the process of terminal differentiation. First,
exogenously expressed p27 in NHEK, expressed at levels suf®cient
to cause growth arrest, are further upregulated following differen-
tiation-inducing treatment (Harvat et al, 1998). Second, low levels
of p27 expression in head and neck, esophageal, and non-small-cell
lung SCC tumors are associated with poor prognosis and lack of
differentiation (Jordan et al, 1998; Yatabe et al, 1998; Catzavelos
et al, 1999). Third, our studies suggest that the carcinoma cell lines
and HaCaT cells require additional cycles before the effects of IFN-
g are fully realized. This is reminiscent of the response of cells
derived from p27 null mice, which undergo additional cycles in
serum-deprived culture before they become quiescent compared to
wildtype cells (Kiyokawa and Koff, 1998). Thus, if tumor cells have
even a modest inability to regulate p27 levels or its association with
cdk, the consequences, although not necessarily tumorigenic
themselves, could have dramatic effects on tumor growth and
differentiation. Recent reports have indicated that aberrant cellular
localization of p27 may have a role in tumorigenesis (Ciaparrone
et al, 1998; Orend et al, 1998; Singh et al, 1998). This could
potentially be one reason for the failure to detect changes in levels
of the cki proteins in cdk2 complexes in SCC cells. Further studies
to determine the localization of p27 in SCC cell lines and whether
that contributes to the inability of these cells to respond to IFN-g
are in progress.
Taken all together, these ®ndings suggest that IFN-g is able to
affect multiple cki in NHEK, causing the inhibition of G1 cdk and
thus the inhibition of G1 to S phase progression. SCC cell lines
appear to have a delayed/reduced response to the growth arrest
effects of IFN-g, which is due at least in part to their inherent
inability to properly regulate the cki and p130 expression.
Upstream IFN-g signaling events, however, appear to be intact in
these cells. Details of the precise mechanisms that are defective in
regulating p27, p21, and p130 levels and their function in the
insensitive cell lines remain to be worked out. We have demon-
strated that p53 status of SCC tumors may affect the level of p21Cip1
expression and that the association of both p21 and p27 with cdk2
may be defective, preventing timely inhibition of its activity during
differentiation. Better understanding of the consequences of these
defects for terminal differentiation should allow for the develop-
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ment of very speci®cally targeted interventions in the treatment of
SCC.
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